Education
About Us
Working with TipRanks
Follow Us
Sanofi SA (SNY)
:SNY
Top Page
Sanofi
(NASDAQ:SNY)
Rating:73Outperform
Price Target:
$51.00
▲(6.61% Upside)
Positive Factors
Earnings
Robust sales from key products and new launches propelled earnings above expectations.
Product Pipeline
Sanofi is expected to launch or expand indications for over 10 drugs in FY25, showcasing a diverse pipeline.
Negative Factors
Competition
Competition from alternatives of Dupixent could risk its market share being diminished.
Safety Concerns
Qfitlia requires liver tests and monitoring for signs and symptoms of acute and recurrent gallbladder disease, indicating potential safety concerns.
Sanofi (SNY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$0.00
Dividend Yield4.62%
Average Volume (3M)2.12M
Price to Earnings (P/E)11.9
Beta (1Y)0.00
Revenue Growth-9.32%
EPS Growth120.62%
CountryUS
Employees82,878
SectorHealthcare
Sector Strength38
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.91
Shares Outstanding0
10 Day Avg. Volume2,823,107
30 Day Avg. Volume2,119,288
Financial Highlights & Ratios
PEG Ratio3.23
Price to Book (P/B)1.50
Price to Sales (P/S)2.63
P/FCF Ratio19.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$61.20Price Target Upside27.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Sanofi Business Overview & Revenue Model
Company DescriptionSanofi (SNY) is a global healthcare leader engaged in the research, development, manufacturing, and marketing of therapeutic solutions. The company operates across various sectors, including pharmaceuticals, vaccines, and consumer healthcare. Sanofi's core products and services include prescription medicines, vaccines for adults and children, and over-the-counter healthcare products. With a robust pipeline and a strategic focus on emerging markets, Sanofi aims to address a wide range of healthcare needs worldwide.
How the Company Makes MoneySanofi makes money primarily through the sale of its pharmaceutical products, vaccines, and consumer healthcare products. The company's revenue streams are largely driven by its pharmaceuticals segment, which includes specialty care and general medicines. Specialty care focuses on rare diseases, oncology, immunology, multiple sclerosis, and more, while general medicines cover diabetes, cardiovascular, and established prescription products. The vaccines segment, operated through Sanofi Pasteur, is a significant contributor to Sanofi's earnings, offering vaccines for diseases like influenza, meningitis, and polio. Additionally, the consumer healthcare division provides over-the-counter products that cater to wellness and self-care needs. Strategic partnerships, research and development collaborations, and expansion into high-growth markets further bolster Sanofi's revenue potential.
Sanofi Earnings Call Summary
Earnings Call Date:Jul 31, 2025
(Q2-2025)
| % Change Since: -2.86%|
Next Earnings Date:Oct 24, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong sales growth driven by Dupixent and strategic acquisitions, but also pointed out challenges including mixed trial results for itepekimab and anticipated declines in flu vaccine sales. Despite these challenges, the company remains optimistic about future growth and sustainability efforts.Q2-2025 Updates
Positive Updates
Strong Q2 Performance
Sanofi delivered a strong quarter with double-digit sales growth, achieving a 10.1% increase in net sales at constant exchange rates.
Dupixent Sales Surge
Dupixent sales reached EUR 3.8 billion, up 21% in Q2, driven by continued strong demand and improved indications across geographies.
Successful Strategic Acquisitions
Sanofi completed significant acquisitions including Blueprint Medicines, strengthening its position in rare immunology diseases.
Sustainability Recognition
TIME ranked Sanofi as the world's 10th most sustainable company across all industries and #1 in pharma and biotech.
Vaccine Business Growth
Vaccine sales increased by 10.3%, driven by the expansion of Beyfortus and benefiting from the late 2024-2025 flu season.
Negative Updates
Mixed Results for Itepekimab
Sanofi reported mixed Phase III results for itepekimab in COPD, leading to ongoing analysis and discussions with regulatory authorities.
Flu Vaccine Sales Decline
Total flu vaccine sales are expected to decrease by a mid-teens percentage due to competitive forces, particularly in the U.S. and Germany.
Increased R&D and SG&A Expenses
R&D expenses increased by 17.7% and SG&A expenses also saw an increase, reflecting investments in new launches and future growth.
Regeneron Reimbursement Impact
The end of Regeneron’s reimbursement of R&D costs is expected to negatively impact Sanofi's BOI by approximately EUR 300 million in 2026 and EUR 800 million in 2027.
Company Guidance
In the Q2 2025 conference call, Sanofi provided updated guidance, indicating a high single-digit percentage sales growth at constant exchange rates for the full year. This confidence is bolstered by strong performance in Q2, with net sales increasing by 10.1% at constant exchange rates. Key contributors to this growth include double-digit sales increases driven by new launches, vaccines, and Dupixent, which alone saw a 21% rise to EUR 3.8 billion. Sanofi's pipeline remains strong despite some mixed results, with significant contributions from new launches, collectively representing 10% of total sales. The company is also executing a EUR 5 billion share buyback program, with over 80% completed, and continues to anticipate a low double-digit percentage growth in business EPS at constant exchange rates.Sanofi Financial Statement Overview
Summary
Sanofi demonstrates financial stability with strong profitability and a solid balance sheet. However, the decline in free cash flow growth indicates potential limitations for future investments, despite healthy margins and low leverage.Income Statement
Sanofi's income statement shows moderate performance with a stable gross profit margin of 71% TTM. The net profit margin improved to 14.4% TTM, indicating efficient cost management. However, revenue growth is slightly negative compared to the previous year, reflecting potential challenges in market expansion. EBIT and EBITDA margins are healthy at 18.5% and 23.0% TTM, respectively.78
Positive
Balance Sheet
Sanofi maintains a solid balance sheet with a debt-to-equity ratio of 0.28, reflecting low leverage and financial stability. The return on equity (ROE) is strong at 8.5% TTM, demonstrating effective use of shareholder funds. The equity ratio stands at 56.1% TTM, indicating a robust capital structure with sufficient equity backing.75
Positive
Cash Flow
Sanofi's cash flow analysis reveals a decline in free cash flow growth, falling by 73% TTM, which could constrain future investments. However, the operating cash flow to net income ratio is robust at 0.56, showcasing healthy cash conversion from profits. The free cash flow to net income ratio is lower at 0.25, signaling room for improvement in cash retention.65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.77B | 44.29B | 46.03B | 45.39B | 39.17B | 37.37B |
| Gross Profit | 31.14B | 31.08B | 31.80B | 31.70B | 26.92B | 25.21B |
| EBITDA | 10.09B | 11.03B | 12.00B | 14.06B | 11.29B | 17.51B |
| Net Income | 6.30B | 5.56B | 5.40B | 8.37B | 6.22B | 12.29B |
Balance Sheet | ||||||
| Total Assets | 131.89B | 132.80B | 126.46B | 126.72B | 120.24B | 114.41B |
| Cash, Cash Equivalents and Short-Term Investments | 7.99B | 7.93B | 8.71B | 12.74B | 10.10B | 13.91B |
| Total Debt | 21.05B | 17.91B | 18.42B | 21.21B | 22.41B | 23.68B |
| Total Liabilities | 57.47B | 54.94B | 52.11B | 51.57B | 51.21B | 51.16B |
| Stockholders Equity | 74.07B | 77.51B | 74.04B | 74.78B | 68.68B | 63.11B |
Cash Flow | ||||||
| Free Cash Flow | 1.59B | 5.89B | 7.35B | 8.32B | 8.48B | 5.33B |
| Operating Cash Flow | 3.52B | 9.08B | 10.26B | 10.53B | 10.52B | 7.45B |
| Investing Cash Flow | -4.19B | -4.41B | -6.20B | -2.08B | -7.30B | 3.59B |
| Financing Cash Flow | -503.00M | -5.76B | -8.05B | -5.82B | -7.06B | -6.49B |
Sanofi Technical Analysis
Negative
47.84
Price Trends
49.08
Negative
50.56
Negative
50.26
Negative
Market Momentum
-0.35
Positive
45.79
Neutral
48.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNY, the sentiment is Negative. The current price of 47.84 is below the 20-day moving average (MA) of 48.63, below the 50-day MA of 49.08, and below the 200-day MA of 50.26, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 45.79 is Neutral, neither overbought nor oversold. The STOCH value of 48.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNY.
Sanofi Risk Analysis
Sanofi disclosed 29 risk factors in its most recent earnings report. Sanofi reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations Q4, 2023
2.
Failure to comply with data ethics and privacy regulations could adversely affect our business and reputation Q4, 2023
3.
A failure in our crisis and business continuity management processes in case of unpredictable events could have negative consequences for our business, operations and reputation Q4, 2023
Sanofi Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $231.36B | 27.79 | 19.76% | 2.08% | 15.17% | 29.15% | |
78 Outperform | $224.92B | 16.95 | 32.82% | 3.46% | 12.83% | -11.92% | |
73 Outperform | $0.00 | 11.95 | 8.39% | 4.62% | -9.32% | 120.62% | |
71 Outperform | $139.89B | 24.08 | 32.51% | 2.77% | 4.63% | 1144.01% | |
67 Neutral | $0.00 | 18.32 | 29.31% | 5.37% | 2.57% | ― | |
66 Neutral | $140.71B | 12.51 | 12.16% | 6.91% | 13.38% | ― | |
51 Neutral | $7.38B | 0.42 | -62.86% | 2.37% | 15.61% | -1.95% |
* Healthcare Sector Average
Performance Comparison
SNY
Sanofi
47.84
-2.36
-4.70%
AZN
AstraZeneca
74.48
-4.55
-5.76%
BMY
Bristol-Myers Squibb
45.85
1.44
3.24%
GILD
Gilead Sciences
112.46
40.77
56.87%
NVS
Novartis
117.73
9.84
9.12%
PFE
Pfizer
24.75
-2.21
-8.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.